metastatic castration-resistant prostate cancer

• Business
• Financial
• Healthcare
• Industrial
• Investment
• Management
• Marketing
• News
• Pharma & Biotech
• Science
• Security & Safety
• Switzerland
• Technology

Novartis Announces Positive Interim Results for Pluvicto™ in Early-Stage Prostate Cancer, Meeting Primary Endpoint in Phase III PSMAddition Trial

(IN BRIEF) Novartis has announced that its Phase III PSMAddition trial of Pluvicto™ in combination with standard of care (SoC)…